|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||12.94 / 18.86|
"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax. A consecutive nine-day market drop was snapped as we regained most that was lost in that period. Today was a great day. (Boy, would I like to annualize the pe...
For the week of November 7, all eyes will be on Tuesday's presidential election.
Thursday felt a lot like capitulation in this space. I was buying.
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.
Shares of the drug distributor were falling sharply Friday.
The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.
The likely continuation of a split government should help the sector recover from its recent beat-down.
With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.
Thanks to everyone who contributed to the conversation on the Daily Diary today. It was quite a lively bunch. I wish the market could have held earlier highs, but at least it was a positive end to a volatile trading week and a downright brutal one f...
U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Mylan rose after settling with the U.S. Department of Justice for $465 million over the way it overcharged Medicaid for the EpiPen.
Two U.S. senators claim EpiPen maker Mylan overcharged Medicaid for some twenty years to the tune of millions of dollars.
Mylan's generic EpiPen will come this year, but later than originally expected.
Brexit concerns pummel the pound while Alphabet gets set to unveil several new devices.
U.S. stocks fall into the red by late Thursday morning as Mylan kicks off a selloff in health care.
U.S. stocks ended near lows as Wall Street grew restless ahead of the first presidential debate.
Andrew Left says cracking down on Big Pharma may be all that Hillary Clinton and Donald Trump have in common.
It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
And what happened to all those predicting a surprise rate hike?
Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
The Bank of Japan introduces a zero percent interest-rate target for 10 year government bonds to step up its fight against deflation.
It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.
Mylan dealing with more negative reports, this time for executive pay.
Bayer has agreed to purchase Monsanto for $66 billion, or $128 a share, a 20% premium over its previous closing price.